Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jory R Baldridge

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Endotoxin Research|October 25, 2006
TLR4 agonists as immunomodulatory agentsMark R Alderson, Patrick McGowan, Jory R Baldridge, et al.
Expert Opinion on Biological Therapy|July 23, 2004
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agentsJory R Baldridge, Patrick McGowan, Jay T Evans, et al.
Expert Review of Vaccines|August 6, 2003
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529Jay T Evans, Christopher W Cluff, David A Johnson, et al.
Vaccine|July 13, 2016
Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvantsAlyson J Smith, Yufeng Li, Hélène G Bazin, et al.
Trends in Microbiology|October 16, 2002
Taking toll: lipid A mimetics as adjuvants and immunomodulatorsDavid H Persing, Rhea N Coler, Michael J Lacy, et al.
Journal of Endotoxin Research|April 17, 2003
Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529Jory R Baldridge, Christopher W Cluff, Jay T Evans, et al.
Infection and Immunity|April 23, 2005
Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challengeChristopher W Cluff, Jory R Baldridge, Axel G Stöver, et al.
The Journal of Biological Chemistry|October 23, 2003
Structure-activity relationship of synthetic toll-like receptor 4 agonistsAxel G Stöver, Jean Da Silva Correia, Jay T Evans, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Endotoxin Research|October 25, 2006
TLR4 agonists as immunomodulatory agentsMark R Alderson, Patrick McGowan, Jory R Baldridge, et al.
Expert Opinion on Biological Therapy|July 23, 2004
Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agentsJory R Baldridge, Patrick McGowan, Jay T Evans, et al.
Expert Review of Vaccines|August 6, 2003
Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529Jay T Evans, Christopher W Cluff, David A Johnson, et al.
Vaccine|July 13, 2016
Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvantsAlyson J Smith, Yufeng Li, Hélène G Bazin, et al.
Trends in Microbiology|October 16, 2002
Taking toll: lipid A mimetics as adjuvants and immunomodulatorsDavid H Persing, Rhea N Coler, Michael J Lacy, et al.
Journal of Endotoxin Research|April 17, 2003
Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): induction of protective innate immune responses by RC-524 and RC-529Jory R Baldridge, Christopher W Cluff, Jay T Evans, et al.
Infection and Immunity|April 23, 2005
Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challengeChristopher W Cluff, Jory R Baldridge, Axel G Stöver, et al.
The Journal of Biological Chemistry|October 23, 2003
Structure-activity relationship of synthetic toll-like receptor 4 agonistsAxel G Stöver, Jean Da Silva Correia, Jay T Evans, et al.
Pageof 1